“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
Why are advocacy and accessibility so important to rare diseases such as Batten Disease? On this week’s Few & Far Between podcast episode, Biorasi’s...
"We have to rethink the sense of clinical research from the point of view that if we have the possibility to have markers that...
On today’s podcast, host Wayne Bowden, Vice President of Partnerships and Strategy at Biorasi, will be talking with Julie Walters, Founder and Executive Director...